164 related articles for article (PubMed ID: 31384313)
1. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.
Tong Z; Mejia A; Veeranki O; Verma A; Correa AM; Dokey R; Patel V; Solis LM; Mino B; Kathkuda R; Rodriguez-Canales J; Lin SH; Krishnan S; Kopetz S; Blum M; Ajani JA; Hofstetter WL; Maru DM
Ther Adv Med Oncol; 2019; 11():1758835919864850. PubMed ID: 31384313
[TBL] [Abstract][Full Text] [Related]
2. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.
Veeranki OL; Tong Z; Dokey R; Mejia A; Zhang J; Qiao Y; Singh PK; Katkhuda R; Mino B; Tailor R; Canales JR; Bassett R; Ajani J; Wu JY; Kopetz S; Blum M; Hofstetter W; Tetzlaff M; Krishnan S; Lin SH; Maru D
Oncotarget; 2019 Jul; 10(45):4703-4718. PubMed ID: 31384397
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma.
Tong Z; Chatterjee D; Deng D; Veeranki O; Mejia A; Ajani JA; Hofstetter W; Lin S; Guha S; Kopetz S; Krishnan S; Maru D
Oncotarget; 2017 Apr; 8(17):28696-28710. PubMed ID: 28404924
[TBL] [Abstract][Full Text] [Related]
4. Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells.
Pratap A; Qualman A; Garrett H; The E; Chauhan A; Idrovo JP; Cheng L; Wani S; Meguid RA; Meng X
Anticancer Res; 2023 Aug; 43(8):3411-3418. PubMed ID: 37500147
[TBL] [Abstract][Full Text] [Related]
5. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.
Zhang Y; Zhou L; Leng Y; Dai Y; Orlowski RZ; Grant S
Oncotarget; 2017 Aug; 8(35):59476-59491. PubMed ID: 28938651
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
[TBL] [Abstract][Full Text] [Related]
7. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Phillips DC; Jin S; Gregory GP; Zhang Q; Xue J; Zhao X; Chen J; Tong Y; Zhang H; Smith M; Tahir SK; Clark RF; Penning TD; Devlin JR; Shortt J; Hsi ED; Albert DH; Konopleva M; Johnstone RW; Leverson JD; Souers AJ
Leukemia; 2020 Jun; 34(6):1646-1657. PubMed ID: 31827241
[TBL] [Abstract][Full Text] [Related]
8. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
10. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
12. Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.
Chukkapalli V; Gordon LI; Venugopal P; Borgia JA; Karmali R
Oncotarget; 2018 Apr; 9(30):21166-21181. PubMed ID: 29765528
[TBL] [Abstract][Full Text] [Related]
13. miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression.
Wang Y; Zhao Y; Herbst A; Kalinski T; Qin J; Wang X; Jiang Z; Benedix F; Franke S; Wartman T; Camaj P; Halangk W; Kolligs FT; Jauch KW; Nelson PJ; Bruns CJ
Ann Surg; 2016 Nov; 264(5):804-814. PubMed ID: 27501171
[TBL] [Abstract][Full Text] [Related]
14. Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
Harada K; Ferdous T; Harada T; Ueyama Y
Int J Oncol; 2016 Jul; 49(1):276-84. PubMed ID: 27210058
[TBL] [Abstract][Full Text] [Related]
15. Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer.
Blum AE; Venkitachalam S; Ravillah D; Chelluboyina AK; Kieber-Emmons AM; Ravi L; Kresak A; Chandar AK; Markowitz SD; Canto MI; Wang JS; Shaheen NJ; Guo Y; Shyr Y; Willis JE; Chak A; Varadan V; Guda K
Gastroenterology; 2019 May; 156(6):1761-1774. PubMed ID: 30768984
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Qing Y; Wang X; Wang H; Hu P; Li H; Yu X; Zhu M; Wang Z; Zhu Y; Xu J; Guo Q; Hui H
Cell Commun Signal; 2021 Aug; 19(1):83. PubMed ID: 34372855
[TBL] [Abstract][Full Text] [Related]
17. HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
Nakamura J; Kitajima Y; Kai K; Hashiguchi K; Hiraki M; Noshiro H; Miyazaki K
Int J Cancer; 2010 Sep; 127(5):1158-71. PubMed ID: 20020496
[TBL] [Abstract][Full Text] [Related]
18. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma.
Kosovec JE; Zaidi AH; Kelly LA; Rotoloni CL; Vytlacil C; DiCarlo C; Matsui D; Komatsu Y; Boyd NH; Omstead A; Kolano EL; Biederman RW; Finley G; Silverman JF; Landreneau RJ; Jobe BA
Ann Surg; 2016 Aug; 264(2):297-304. PubMed ID: 26445473
[TBL] [Abstract][Full Text] [Related]
20. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Cidado J; Boiko S; Proia T; Ferguson D; Criscione SW; San Martin M; Pop-Damkov P; Su N; Roamio Franklin VN; Sekhar Reddy Chilamakuri C; D'Santos CS; Shao W; Saeh JC; Koch R; Weinstock DM; Zinda M; Fawell SE; Drew L
Clin Cancer Res; 2020 Feb; 26(4):922-934. PubMed ID: 31699827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
